Gelatin Patents (Class 424/456)
  • Patent number: 11207293
    Abstract: The present invention discloses a composition and method of use for the general improvement of hypertension, high cholesterol, and cardiovascular health. The novel composition is comprised of thiamin (vitamin B1), vitamin B2 (as riboflavin-5?-phosphate), niacin (vitamin B3, as niacinamide), vitamin B6 (as pyridoxine hydrochloride), folic acid, vitamin C, vitamin D, calcium (as calcium carbonate), magnesium (as magnesium taurate), aged garlic extract, olive leaf extract (as 20% oleuropein), coenzyme Q10 (as ubiquinol), L-Arginine (as hydrochloride), L-Citrulline (as malate), and lycopene.
    Type: Grant
    Filed: July 1, 2018
    Date of Patent: December 28, 2021
    Inventor: Anthony Stampalia
  • Patent number: 11173155
    Abstract: Disclosed in certain embodiments is an immediate release solid oral dosage form comprising a plurality of particles, each particle comprising: (i) a core comprising a first active agent; (ii) a coating comprising a second active agent layered over the core; and (iii) a material that is sensitive to acidic pH layered over the coated core; wherein the dosage form releases at least about 70% of the second active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: November 16, 2021
    Assignee: Rhodes Pharmaeuticals, L.P.
    Inventors: Akwete L. Adjei, Sibao Chen, Robert J. Kupper, Vincent Mancinelli
  • Patent number: 11160781
    Abstract: Apparatuses, methods, and systems for extraction, isolation, purification, and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith are presented. A method for preparing a whole-plant hemp extract based product includes extracting cannabinoids from plant materials, such as one or more hemp varieties of Cannabis sativa. The method also includes separating and purifying CBD from the extracted cannabinoids, converting purified CBD to ?9-THC and ?8-THC and concurrently converting ?9-THC to CBN, purifying and separating the CBN, and combining the purified CBN with a whole-plan hemp extract. Products and supplements related to the method are also described.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: November 2, 2021
    Assignee: Charlotte's Web, Inc.
    Inventors: Alexander Michael McCorkle, Graham Taylor Carlson, Shelby Renee Sheahan
  • Patent number: 11141399
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: October 12, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Patent number: 11123296
    Abstract: The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: September 21, 2021
    Assignee: Novo Nordisk A/S
    Inventor: Thomas Vilhelmsen
  • Patent number: 11102996
    Abstract: Sweetener and flavor compositions with improved taste profiles are disclosed. Also disclosed are methods of making and methods of using such sweetener and flavor compositions.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: August 31, 2021
    Assignees: EPC NATURAL PRODUCTS CO., LTD.
    Inventors: Jingang Shi, Hansheng Wang, Xin Shi, Yi Wang, Wei Lyu, Yingxiang Xin, Thomas Eidenberger, Weiyao Shi
  • Patent number: 11096887
    Abstract: Pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: August 24, 2021
    Assignee: SpecGX LLC
    Inventors: Brad L. Gower, Carlos H. Castaneda, Jae Han Park, Clifford J. Herman
  • Patent number: 11096936
    Abstract: This invention relates to cocrystals of naloxone and of naltrexone and their use as opioid antagonists. The cocrystals of the invention include naloxone isonicotinamide cocrystal, naloxone hydrochloride piperazine cocrystal, naltrexone menthol cocrystal, naltrexone thymine cocrystal, naltrexone 2,5-dihydroxybenzoic acid cocrystal, naltrexone salicylic acid cocrystal, naltrexone hydrochloride piperazine cocrystal and naltrexone hydrochloride sulfathiazole cocrystal. A drug-in¬ adhesive transdermal patch containing the opioid analgesic fentanyl or an analog thereof and a cocrystal of naloxone or naltrexone is disclosed. Also disclosed is a method of treating pain, such as acute, chronic or intermittent pain, by applying a drug-in-adhesive transdermal patch of the invention to the skin of a patient in need thereof.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: August 24, 2021
    Assignee: Cassava Sciences, Inc.
    Inventors: Remi Barbier, Nadav Friedmann, Vijay Srirambhatla, Stephen Watt, Michael Zamloot
  • Patent number: 11033523
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: June 15, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 11013709
    Abstract: The present invention relates to a method of administering an effective dose of highly purified eicosapentaenoic acid as free-fatty acid (EPA-FFA) to reduce fecal calprotectin levels and reduce the risk of clinical relapse in UC patients. The eicosapentaenoic acid, in the free fatty acid (EPA-FFA) form, has a purity of at least 95%, and more preferably at least 99%.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: May 25, 2021
    Assignee: S.L.A. PHARMA AG
    Inventor: Justin Slagel
  • Patent number: 10993987
    Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 4, 2021
    Assignee: Sublimity Therapeutics Limited
    Inventors: Ivan Coulter, Vincenzo Aversa, Mónica Torres Rosa, Dáire O'Donnell, Wyatt Renaud of Calhane
  • Patent number: 10987385
    Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: April 27, 2021
    Assignee: Finch Therapeutics Holdings LLC
    Inventor: Thomas Julius Borody
  • Patent number: 10980773
    Abstract: Apparatuses, methods, and systems for extraction, isolation, purification, and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith are presented. A method for preparing a whole-plant hemp extract based product includes extracting cannabinoids from plant materials, such as one or more hemp varieties of Cannabis sativa. The method also includes separating and purifying CBD from the extracted cannabinoids, converting purified CBD to ?9-THC and ?8-THC and concurrently converting ?9-THC to CBN, purifying and separating the CBN, and combining the purified CBN with a whole-plan hemp extract. Products and supplements related to the method are also described.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: April 20, 2021
    Assignee: Charlotte's Web, Inc.
    Inventors: Alexander Michael McCorkle, Graham Taylor Carlson, Shelby Renee Sheahan
  • Patent number: 10934398
    Abstract: The present invention relates to an improved method for producing a colloidal nitrocellulose dispersion made compatible with a system of acrylic monomers polymerized with surfactants in a water-based system under pressure. The self-emulsifiable system of the present invention is characterized by the latex formed by the nitrocellulose suspension in an aqueous medium, with nanometric particles and homogeneity and, consequently, a greater covering and smoothing power, high adherence, high gloss, greater chemical and mechanical resistance, rapid drying, less water retention when used in paints, varnish and sealant compositions for coatings in the fields of graphic printing, such as flexography and rotogravure, lamination, nail polish, metal-mechanics, decoration, glass, leather, plastics, wood surfaces, compounds and mortars, decorative wall paints, textiles, paper coatings and car paint repairs, inter alia.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 2, 2021
    Assignee: Companhia Nitro Quimica Brasileira
    Inventors: Ludmila De Carvalho Fidale, Reginaldo Faichel Da Silva
  • Patent number: 10925829
    Abstract: The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrate in a patient's oral cavity.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: February 23, 2021
    Assignee: Handa Neuroscience, LLC
    Inventor: Fangyu Liu
  • Patent number: 10918630
    Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 16, 2021
    Inventors: Kamal Surendrakumar Mehta, Saurabh Srivastava, Dinesh Kumar, Amit Kumar Jha, Subash Chandra Mohanta, Sunil Kumar Panda, Ganesh Vinayak Gat
  • Patent number: 10905142
    Abstract: According to embodiments, a dry powdered composition which may be reconstituted to provide a gelatin product includes powdered gelatin and a pelletized colorant. The pelletized colorant includes a pigment-protein complex and at least one encapsulating agent for encapsulating the pigment-protein complex. The pelletized colorant has a rate of dissolution a rate of dissolution of less than 2 grams/minute in water having an initial temperature of from about 95° C. to about 100° C. Methods of making food products with the pelletized colorant are also disclosed. In embodiments, when the food products are measured on the L*a*b* color space, the food products have an L* value of about 49 to about 57, an a* value of about ?10 to about ?16, and a b* value of from about ?11 to about ?20.5.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: February 2, 2021
    Assignee: Kraft Foods Group Brands LLC
    Inventors: Andrew E. McPherson, John Topinka, Sara Rice
  • Patent number: 10898873
    Abstract: The present invention is directed towards compositions comprising a lecithin; a sugar alcohol, a sugar, or combinations of any thereof; and an alcohol. Compositions comprising a water soluble surfactant are further disclosed. Methods of separating oil from a mixture are disclosed. Methods of dispersing an oil are further disclosed. Compositions comprising a water-dilutable microemulsion are disclosed. Methods of making chewing gum are disclosed. Methods of recovering oil from a mixture are further disclosed.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 26, 2021
    Assignee: ARCHER DANIELS MIDLAND COMPANY
    Inventor: Shireen S. Baseeth
  • Patent number: 10894049
    Abstract: The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: January 19, 2021
    Assignee: Shenzhen Pharmacin Co., Ltd.
    Inventors: Zeren Wang, Jun Xu, Long Qu
  • Patent number: 10864223
    Abstract: The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: December 15, 2020
    Assignee: Aker BioMarine Antarctic AS
    Inventors: Finn Myhren, Nils Hoem, Asgeir Saebo, Anil R. Oroskar, Asha A. Oroskar, Anantha Krishna Mallia
  • Patent number: 10842830
    Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Pendulum Therapeutics, Inc.
    Inventors: Colleen Cutcliffe, John S. Eid, James H. Bullard, Marcus F. Schicklberger
  • Patent number: 10813937
    Abstract: The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: October 27, 2020
    Assignee: Shenzhen Pharmacin Co., Ltd.
    Inventors: Zeren Wang, Jun Xu, Long Qu
  • Patent number: 10779561
    Abstract: A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, and at least one medium-chain triglyceride.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: September 22, 2020
    Assignee: AQUANOVA AG
    Inventor: Dariush Behnam
  • Patent number: 10758562
    Abstract: A supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals is disclosed. The supplement is in a gel form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise a vegetable oil, B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. The amount of mastic gum is from about 1 to about 6 grams per 10 cubic centimeters of gel.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 1, 2020
    Assignee: KAECO Group, Inc.
    Inventors: Kelly Terry, Leon Kratochvil, James Harless, Tom Kratochvil
  • Patent number: 10744102
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 18, 2020
    Assignee: Epizon Pharma, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Patent number: 10744131
    Abstract: Disclosed are abuse resistant oral pharmaceutical compositions that reduce the likelihood of improper administration of drugs that are susceptible to abuse. The oral pharmaceutical formulations contain abuse deterrent agents that cause discomfort to the user when administered in an improper manner and make the extraction of an active ingredient more difficult. Methods of making and using the compositions are also disclosed.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: August 18, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Harpreet Kaur Sandhu, Siva Ram Kiran Vaka, Ashish Chatterji, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Patent number: 10744101
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 18, 2020
    Assignee: Epizon Phama, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Patent number: 10736843
    Abstract: Methods of enhancing cognition and/or memory and methods of treating cognitive and cerebrovascular disorders by intranasally administering an in situ gelling composition comprising micelles formed with tocopherol or a derivative thereof are provided. The micelles encapsulate a biological active agent such as vinpocetine. The methods provide for enhanced brain targeting of the biological active agent.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: August 11, 2020
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Tarek A. Ahmed, Khalid M. El-Say, Osama A. A. Ahmed, Bader M. Aljaeid
  • Patent number: 10722527
    Abstract: Abiraterone acetate lipid formulations.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: July 28, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Hywel Williams, Prashant Agarwal, Eduardo Jule
  • Patent number: 10688066
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: June 23, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10688097
    Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 23, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li
  • Patent number: 10675276
    Abstract: The present invention relates to two novel oral pharmaceutical compositions of dabigatran etexilate or its pharmaceutically acceptable salts thereof, and the processes of preparation thereof.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: June 9, 2020
    Assignee: HANGZHOU SOLIPHARMA CO., LTD.
    Inventors: Xiaoxia Sheng, Yong Tang
  • Patent number: 10662120
    Abstract: A process for providing fluoresence to a dental ceramic body by treating at least a portion of the outer surface of the dental ceramic body or a precursor thereof with a bismuth containing substance, characterized by the steps of placing the dental ceramic body or the precursor thereof into a closeable container, in particular a crucible; generating a bismuth containing atmosphere in the container and exposing at least a portion of the outer surface of the dental ceramic body or of the precursor to the bismuth containing atmosphere at a temperature above 1000° C.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: May 26, 2020
    Assignee: STRAUMANN HOLDING AG
    Inventors: Alexander Zwahlen, Marc Stephan
  • Patent number: 10660859
    Abstract: The present disclosure relates to a novel aqueous coating composition comprising a polymer, at least one glidant, and at least one emulsifier, and at least one plasticizer, for soft capsule shells or softgel capsules, providing an enteric release profile, and to a method of enteric coating of soft capsule shells or containers; and to the resulting enteric coated soft capsule shells or softgel capsules with the aqueous coating composition.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 26, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Jan Vertommen, Marie Sophie Martina
  • Patent number: 10646495
    Abstract: Testosterone ester triglyceride formulations, optionally further including adducts. Methods of in-situ control of the manufacture or formation of such adducts are also described.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: May 12, 2020
    Assignee: Antares Pharma, Inc.
    Inventor: Shaowei Ong
  • Patent number: 10617761
    Abstract: The invention relates to polysiloxanes contained as defoaming agents, amongst other things, in medicinal compositions such colon cleansing solutions and antiflatulants. The aim of the invention is to further improve the defoaming effect of polysiloxanes and also the compatibility of the agents. According to the invention, the use of calcium sulphate increases the defoaming effect of dimeticon or simeticon as polysiloxane defoaming agents. The invention also relates to PEG-containing colon cleaning solutions based thereon.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 14, 2020
    Assignee: REGALISMONS S.A.
    Inventor: Uwe Willi Albrecht
  • Patent number: 10617699
    Abstract: The present invention relates to an orally administrable pharmaceutical dosage form for use in the prevention and/or treatment of a cardiovascular disease which includes (a) acetylsalicylic acid as a first active agent and (b) HMG-CoA reductase inhibitor as a second active agent. The HMG-CoA reductase inhibitor is selected from atorvastatin and rosuvastatin and salts thereof. The present invention is formulated in (a) two or more single separate coated dosage units in which the coating includes one or more water-soluble polymer and no more than 0 to 5% by weight of the coating of water-insoluble or enteric polymer, and in which the dosage units include 8 to 12 mg/cm2 coating and show an immediate release profile; and (b) one or more single separate coated dosage units.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: April 14, 2020
    Assignees: FERRER INTERNACIONAL, S.A., FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
    Inventors: Pablo Martin Sanz, Javier Urbano Hurtado
  • Patent number: 10576118
    Abstract: Methods of improving or enhancing sexual conditions in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are described. Methods of improving sexual functions, preventing further decline of sexual hormones, and/or improving sexual hormonal level in an aging male human subject, by administering fenugreek or fenugreek seeds, or an extract of fenugreek or fenugreek seeds, are also described.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 3, 2020
    Assignee: GE Nutrients, Inc.
    Inventors: Sunil Bhaskaran, Ramasamy Varadarajan Venkatesh, Jith Veeravalli
  • Patent number: 10537562
    Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 21, 2020
    Assignee: Jubilant Generics Limited
    Inventors: Kamal Surendrakumar Mehta, Saurabh Srivastava, Dinesh Kumar, Amit Kumar Jha, Subash Chandra Mohanta, Sunil Kumar Panda, Ganesh Vinayak Gat
  • Patent number: 10525018
    Abstract: The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 7, 2020
    Assignee: FAES FARMA, S.A.
    Inventors: Josep María Suñé Negre, Ignacio Ortega Azpitarte, Pepa Del Arenal Barrios, Gonzalo Hernández Herrero
  • Patent number: 10526238
    Abstract: A method of forming a dissolvable part of amorphous borate includes: preparing a mixture comprising one or more boron compounds and one or more alkali compounds, at least one of the one or more boron compounds and the one or more alkali compounds being hydrous; heating the mixture to a melting temperature for a predetermined time to melt the mixture and release water from the mixture to form an anhydrous boron compound that is moldable, wherein the amount of alkali compound being selected to achieve an alkali oxide content of between about 10 to 25%; with the anhydrous boron compound at a molding temperature, molding the anhydrous boron compound in a mold; and cooling the anhydrous boron compound to form a solid.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: January 7, 2020
    Assignee: 1824930 Alberta Ltd.
    Inventors: Wesley Wall, Adam Wall, Ray Whitaker
  • Patent number: 10493065
    Abstract: Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 3, 2019
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Patrick Laughlin Mclean
  • Patent number: 10485753
    Abstract: Pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: November 26, 2019
    Assignee: SpecGX LLC
    Inventors: Brad L. Gower, Carlos H. Castaneda, Jae Han Park, Clifford J. Herman
  • Patent number: 10449070
    Abstract: The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: October 22, 2019
    Assignees: Kinki University, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshimasa Ito
  • Patent number: 10363254
    Abstract: Methods for treating or prophylaxis of a Cryptosporidium infection using compositions comprising a structure disclosed herein. Also provided are pharmaceutical compositions and kits for alleviating the symptoms of, for treating, or for preventing the occurrence of Cryptosporidium infection. The kits comprise one or more compounds having a structure disclosed herein, such as in an oral composition, and instructions for use, storage, and the like.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: July 30, 2019
    Assignee: University of Vermont and State Agricultural College
    Inventors: Christopher D. Huston, Kovi Bessoff, Rajiv Satish Jumani
  • Patent number: 10245273
    Abstract: Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 2, 2019
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Wael Salameh, Panayiotis Constantinides
  • Patent number: 10212957
    Abstract: Disclosed in the present invention is a method for preparing an oil-dispersible carotenoid preparation, comprising (by weight parts): mixing 100 parts of carotenoid microcapsule, 100-400 parts of vegetable oil and 0.1-1 part of oil-soluble antioxidant; and grinding the mixture in a colloid mill in a nitro—gen atmosphere and at 10-30° C. to obtain a uniform oil-dispersible carotenoid preparation, wherein the preparation contains 2%-14% carotenoid with an average particle size of up to 0.1-1 ?m, and 100 parts of carotenoid microcapsule contains 10.5-35.8 parts carotenoid, 0.1-1 part of water-soluble antioxidant, and the remainder is a water-soluble colloid. The advantages of the present invention lie in that the oil-dispersible form has a high stability as the surface of the carotenoid particles is still protected with a dense water-soluble colloid, and that an oil-dispersible carotenoid preparation containing carotenoid with a content of up to 2%-14% and an average particle size of only 0.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: February 26, 2019
    Assignees: ZHEJIANG UNIVERSITY, ZHEJIANG NHU COMPANY LTD.
    Inventors: Dan Qiu, Lifang Shi, Jiandong Li, Zhirong Chen, Jiachao Zhou
  • Patent number: 10206971
    Abstract: Disclosed herein are methods of formulating cyclosporin A Form 2.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Anuradha V. Gore, Prem Swaroop Mohanty, E. Quinn Farnes
  • Patent number: 10072311
    Abstract: The invention relates to novel Lactobacillus strains isolated from sourdough. Also encompassed is a composition comprising at least one of said Lactobacillus strains with optionally additional other microorganisms such as bacteria and/or yeasts. The invention further relates to the use of said Lactobacillus strains or compositions for the manufacture of human food products and food supplement products or animal feed products. Another aspect of the invention is the use of the Lactobacillus strains or the composition of Lactobacillus strains in human or veterinary medicine or in cosmetics.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: September 11, 2018
    Assignee: Ludwig Stocker Hofpfisterei GmbH
    Inventor: Jürgen Mayer
  • Patent number: RE47316
    Abstract: This invention relates to a liquid or semisolid oral drug formulation comprising a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: March 26, 2019
    Assignee: QUATRX PHARMACEUTICALS COMPANY
    Inventors: Veli-Matti Lehtola, Markku Anttila